{"symbol":"BMY","fiscalQuarter":"Q4-2025","reportDate":"2026-02-05","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q4-2025","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Up 3.3%","keyNumbers":[{"metric":"EPS","actual":"$1.26","expected":"N/A","surprise":"+9.28%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the strong performance in key therapeutic areas.","They expressed confidence in the ongoing pipeline development."],"summary":"Overall, management conveyed a positive outlook regarding their product performance. They emphasized the importance of their pipeline but did not provide specific guidance."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report showed a solid EPS beat, which contributed to a 3.3% increase in stock price. The positive surprise in EPS indicates stronger-than-expected profitability, although the lack of revenue data leaves some uncertainty. Investors may be encouraged by management's confidence in their product pipeline.","metaDescription":"Bristol Myers Squibb (BMY) Q4 2025 earnings: EPS beat by 9.28%. Stock up 3.3%. Full breakdown."}}